Debio 4028
Alternative Names: Debio-4028Latest Information Update: 29 Feb 2024
Price :
$50 *
At a glance
- Originator Debiopharm Group
- Class Anti-infectives; Antineoplastics; Antivirals; Immunotherapies
- Mechanism of Action Immunomodulators; Inhibitor of apoptosis protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
- Discontinued Infections; Viral infections
Most Recent Events
- 29 Feb 2024 Preclinical trials in Cancer in Switzerland (unspecified route) (Debiopharm pipeline, February 2024)
- 15 Nov 2020 Discontinued for Infections in Switzerland (PO) (Debiopharm pipeline, November 2020)
- 15 Nov 2020 Discontinued for Viral infections in Switzerland (PO) (Debiopharm pipeline, November 2020)